Cargando…

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia

In pediatric acute myeloid leukemia (AML), fusions involving lysine methyltransferase 2A (KMT2A) are considered hallmarks of aggressive AML, for whom the development of targeted specific therapeutic agents to ameliorate classic chemotherapy and obtain a complete eradication of disease is urgent. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tregnago, Claudia, Benetton, Maddalena, Da Ros, Ambra, Borella, Giulia, Longo, Giorgia, Polato, Katia, Francescato, Samuela, Biffi, Alessandra, Pigazzi, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830338/ https://www.ncbi.nlm.nih.gov/pubmed/35153769 http://dx.doi.org/10.3389/fphar.2021.820191

Ejemplares similares

P435: NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Tregnago, Claudia, et al.
Publicado: (2023)

P414: PATIENT-DERIVED XENOGRAFT MODELS ARE THE LEADING STRATEGY TO IDENTIFY NEW AGENTS FOR PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Da Ros, Ambra, et al.
Publicado: (2023)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics
por: Porcù, Elena, et al.
Publicado: (2021)

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
por: Benetton, Maddalena, et al.
Publicado: (2022)

P1398: INSIGHT INTO ACUTE MYELOID LEUKEMIA INDUCED MSC SECRETOME TO REROUTE THE COURSE OF LEUKEMIA BONE MARROW NICHE
por: Borella, G., et al.
Publicado: (2022)

ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia
por: Germano, Giuseppe, et al.
Publicado: (2017)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
por: Cheung, Laurence C., et al.
Publicado: (2022)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
por: Fukushima, Hiroko, et al.
Publicado: (2017)

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
por: Rausch, Johanna, et al.
Publicado: (2023)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
por: Gaur, Tarang, et al.
Publicado: (2023)

Acute myeloid leukaemia at an early age: Reviewing the interaction between pesticide exposure and KMT2A-rearrangement
por: Pombo-de-Oliveira, Maria S, et al.
Publicado: (2017)

Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement
por: Li, Jun, et al.
Publicado: (2023)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
por: Lap, Coen J., et al.
Publicado: (2021)

Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/ KMT2A rearrangements
por: Yuen, Ka‐Yuk, et al.
Publicado: (2022)

P511: INTEGRATION OF TRANSCRIPTOMIC FEATURES IMPROVES PROGNOSIS PREDICTION OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENTS
por: LI, Jun, et al.
Publicado: (2023)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
por: He, Lixiazi, et al.
Publicado: (2022)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

Widespread myeloid sarcoma with KMT2A rearrangement involving the testis, oral cavity, heart, kidney and gallbladder without bone marrow involvement
por: Kapur, Rohan, et al.
Publicado: (2022)

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
por: Casado, Pedro, et al.
Publicado: (2023)

P527: DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA
por: Matsuo, Hidemasa, et al.
Publicado: (2023)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair
por: Russo, Alessia, et al.
Publicado: (2021)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
por: Zhao, Tianming, et al.
Publicado: (2023)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_damdsdi8ukli8g1a0qee71abg6